Literature DB >> 18835316

Selection of serotype-specific vaccine candidate genes in Actinobacillus pleuropneumoniae and heterologous immunization with Propionibacterium acnes.

Liancheng Lei1, Changjiang Sun, Shuang Lu, Xin Feng, Jiaqi Wang, Wenyu Han.   

Abstract

Actinobacillus pleuropneumoniae (A. pleuropneumoniae) is a highly contagious lethal causative agent of swine pleuropneumoniae. Vaccines for this disease are usually serotype specific. In order to identify immunogenic genes specific to serotypes, two differentially expressed gene cDNA libraries of A. pleuropneumoniae CCVC259 (serotype 1) and CCVC263 (serotype 5) had been constructed by using a cDNA representational difference analysis (cDNA-RDA). From the libraries, six potential vaccine candidate genes expressed only in serotype 1 and 13 genes in serotype 5 were identified by antibody screening after gene expression in vitro with a ribosome display system. Eight sequences out of these exhibited 77-100% identity to the corresponding genes in Propionibacterium acnes. The antisera raised against A. pleuropneumoniae serotypes 1 and 5 were reactive with P. acnes at a titer of 1:6400 and vice versa (ELISA titer, 1:3200). Mice immunized with P. acnes were protected against 10 x LD50 challenge with A. pleuropneumoniae serotypes 1 and 5, and the survival rates were 90% and 95%, respectively. Pigs vaccinated with the P. acnes strain could develop high level antibody cross-reacted with A. pleuropneumoniae and obtain noticeable protection from A. pleuropneumoniae infection. These data demonstrate that there were common antigens between A. pleuropneumoniae and P. acnes, and the cross protectivity highlights the possibility of using P. acnes vaccines for preventing infection by A. pleuropneumoniae.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18835316     DOI: 10.1016/j.vaccine.2008.09.039

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Analysis of the Surface, Secreted, and Intracellular Proteome of Propionibacterium acnes.

Authors:  Yang Yu; Jackson Champer; Jenny Kim
Journal:  EuPA Open Proteom       Date:  2015-06-16

2.  An anti-Propionibacterium acnes antibody shows heterologous resistance to an Actinobacillus pleuropneumoniae infection independent of neutrophils in mice.

Authors:  Jian-Fang Liu; Qiu-Yue Ma; Ri-Ning Zhu; Meng-Jun Cheng; Chun-Tong Bao; Jing-Min Gu; Chang-Jiang Sun; Paul Richard Langford; Wen-Yu Han; Lian-Cheng Lei
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

3.  Genomic differences between Actinobacillus pleuropneumoniae serotypes 5b and 3 and their distribution and transcription among 15 serotypes.

Authors:  Feng Yang; Fang Xie; Yuwen Jiang; Suqing Li; Yanping Xing; Yu Wang; Xin Feng; Wenyu Han; Liancheng Lei
Journal:  Curr Microbiol       Date:  2011-07-20       Impact factor: 2.188

4.  Specific humoral immune response induced by propionibacterium acnes can prevent Actinobacillus pleuropneumoniae infection in mice.

Authors:  Feng Yang; Qiuyue Ma; Liancheng Lei; Jing Huang; Qun Ji; Ruidong Zhai; Lei Wang; Yu Wang; Linxi Li; Changjiang Sun; Xin Feng; Wenyu Han
Journal:  Clin Vaccine Immunol       Date:  2014-01-15

5.  Disease risks associated with free-ranging wild boar in Saskatchewan.

Authors:  Glenna F McGregor; Marcelo Gottschalk; Dale L Godson; Wendy Wilkins; Trent K Bollinger
Journal:  Can Vet J       Date:  2015-08       Impact factor: 1.008

6.  Recombinant tandem epitope vaccination provides cross protection against Actinobacillus pleuropneumoniae challenge in mice.

Authors:  Jiameng Xiao; Jianfang Liu; Chuntong Bao; Rining Zhu; Jingmin Gu; Changjiang Sun; Xin Feng; Chongtao Du; Wenyu Han; Yang Li; Liancheng Lei
Journal:  AMB Express       Date:  2020-07-08       Impact factor: 3.298

7.  Application of representational difference analysis to identify genomic differences between Bradyrhizobium elkanii and B. Japonicum species.

Authors:  René Arderius Soares; Luciane Maria Pereira Passaglia
Journal:  Braz J Microbiol       Date:  2010-12-01       Impact factor: 2.476

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.